Men already in danger genetically for the commonest type of hair loss have a 7 p.c added threat of shedding their hair in the event that they use medicine like Ozempic, Wegovy, and Zepbound for type 2 diabetes and obesity, a brand new research exhibits.
Led by researchers at NYU Langone Well being, the research targeted on the GLP1R gene, which naturally will increase the physique’s ranges of glucagon-like peptide-1 (GLP-1) receptor proteins, and used it as an indicator of GLP-1 agonist exercise. Extra GLP1R exercise means there are extra GLP-1 receptor proteins. The researchers in contrast the presence of GLP1R genes with the presence of genes present in males with androgenetic alopecia, an inherited type of hair loss that follows a sample alongside the highest and entrance of the scalp. Male hair loss circumstances are properly studied, not like hair loss in ladies, which is why the researchers might solely analyze any causal hyperlink to hair loss in males.
Many GLP-1 customers, each women and men, have reported thinning hair as a aspect impact, with researchers to date attributing the shedding to the fast weight reduction pushed by the medicines, which work to control blood sugar and suppress urge for food. Usually, GLP-1 customers have discovered that hair development resumes a number of months after their weight stabilizes. Till now, researchers have solely suspected a genetic connection between GLP-1 use and hair loss.
Published in the Journal of Investigative Dermatology, the research confirmed that the GLP1R genes that naturally trigger increased ranges of GLP-1 receptor proteins usually tend to be current in males who’ve androgenetic alopecia. The researchers then adjusted their evaluation to low cost for recognized dangers of hair loss from hypertension, which is assumed to cut back blood circulate to the scalp, harming hair follicle development. The 7 p.c added threat remained the identical.
Researchers additionally checked their threat evaluation in opposition to different potential drivers of hair loss, together with insulin resistance (a explanation for sort 2 diabetes) and lowered testosterone ranges. Nonetheless, the elevated threat of hair loss from GLP-1 use remained at 7 p.c.
As a result of the research concerned genes lively in each GLP-1 customers and males with hair loss, any overlapping threat, the researchers famous, means that the 2 are biologically linked.
“Our research offers the primary genetic hyperlink between GLP-1 use and an elevated threat of male- sample hair loss from androgenetic alopecia, an affiliation lengthy suspected however till no longer proven scientifically,” mentioned research senior investigator Lynn Petukhova, PhD, an assistant professor within the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman Faculty of Drugs.
“Our findings counsel that, if future experiments show profitable, some males, and presumably ladies too, may very well be screened and benchmarked for his or her threat of hair loss earlier than being prescribed GLP-1 medicines,” mentioned Dr. Petukhova. “We might additionally envision these findings resulting in some GLP-1 customers being prescribed mixture therapies to forestall hair loss, equivalent to minoxidil or another drug.”
Dr. Petukhova mentioned additional analysis is required to know the organic mechanisms that trigger GLP-1 use to weaken hair follicle development. She additionally has plans to research whether or not the hyperlinks seen in males apply to ladies.
For the research, researchers accessed massive, publicly accessible genetic databases, together with the eQTLGen database of 31,684 principally White women and men, and the Advanced Traits Genetics group database of 205,327 principally White males.
Androgenetic alopecia is estimated to have an effect on half of White American males over age 50, and virtually the identical variety of White American females over age 50, predominantly those that are postmenopause.
An estimated 12 p.c of Individuals have used GLP-1 medicine for no different motive than weight reduction, together with one-fifth of ladies ages 50 to 64, in keeping with surveys. Because the first GLP-1 drug (Ozempic) was authorized by the Meals and Drug Administration in 2020, prescriptions for the medicine have greater than tripled.
Reference: Ramessur R, Spindler A, Maas D, et al. A causal impact of elevated GLP1R expression on male-pattern hair loss is usually recommended by 2-sample Mendelian randomization. J Make investments Dermatol. doi: 10.1016/j.jid.2026.07.024
This text has been republished from supplies linked above. Word: materials could have been edited for size and content material. For additional data, please contact the cited supply.
